Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 9,512 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

NCT03408899
View directory record Official record
Conditions
HIV Infections
Interventions
PC-1005 gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting Phase 3 Interventional

RA-PRO PRAGMATIC TRIAL

NCT04692493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
targeted synthetic DMARD class, non-TNFi-biologic class
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
48
States / cities
Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis

NCT00038714
View directory record Official record
Conditions
Papilloma, Recurrent Respiratory Papillomatosis
Interventions
SGN-00101
Drug
Lead sponsor
Nventa Biopharmaceuticals Corporation
Industry
Eligibility
2 Years to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
8
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2007 · Synced Oct 17, 2026, 11:03 AM EDT
Terminated Phase 1 Interventional

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

NCT02386111
View directory record Official record
Conditions
Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms, Neoplasms by Histologic Type, Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Combination of varlilumab and sunitinib
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

NCT04279314
View directory record Official record
Conditions
Rett Syndrome
Interventions
Trofinetide
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 21 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting No phase listed Observational

Muscle Recovery After Critical Illness

NCT05537298
View directory record Official record
Conditions
ICU Acquired Weakness, Post Intensive Care Unit Syndrome, Muscle Weakness, Critical Illness
Interventions
Not listed
Lead sponsor
Esther Dupont-Versteegden
Other
Eligibility
18 Years and older · Male only
Enrollment
209 participants
Timeline
2022 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Lexington, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting Phase 3 Interventional

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

NCT01231516
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572, Raltegravir, GSK1349572 Placebo, Raltegravir Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes

NCT05505565
View directory record Official record
Conditions
PreDiabetes, Obesity, Insulin Resistance
Interventions
Abbott Freestyle Libre 2, Standard physical activity and nutritional counseling for prediabetes management
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Active, not recruiting Not applicable Interventional

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

NCT05174767
View directory record Official record
Conditions
Acute Aortic Dissection
Interventions
AMDS
Device
Lead sponsor
Artivion Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

TRC-PAD Program: In-Clinic Trial-Ready Cohort

NCT04004767
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

NCT04435600
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Ustekinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107
View directory record Official record
Conditions
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
792
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

NCT00638807
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
33
States / cities
Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Obesity Risk in African American Women is Determined by a Diet-by-phenotype Interaction

NCT03499509
View directory record Official record
Conditions
Diet Modification
Interventions
Low Glycemic Diet, High Glycemic Diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Magic Camp for Children With Hemiplegic Cerebral Palsy

NCT03620279
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Magic camp intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 17, 2026, 11:03 AM EDT
Terminated Not applicable Interventional

A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension

NCT02895386
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
ROX Coupler, Sham procedure
Device · Other
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 17, 2026, 11:03 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
BMS-986453, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro20
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 17, 2026, 11:03 AM EDT
Completed No phase listed Observational

A Multicenter Study to Evaluate the Cios Spin and the Ion Endoluminal System for Pulmonary Nodule Biopsy

NCT05562895
View directory record Official record
Conditions
Lung Cancer
Interventions
Ion Endoluminal System and Cios Spin
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 17, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of TRC105 and Sorafenib in Patients With HCC

NCT02560779
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Carotuximab (TRC105), Sorafenib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 17, 2026, 11:03 AM EDT